X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DISHMAN PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DISHMAN PHARMA LUPIN LTD/
DISHMAN PHARMA
 
P/E (TTM) x 17.1 25.1 68.3% View Chart
P/BV x 4.0 3.3 119.3% View Chart
Dividend Yield % 0.8 0.7 116.2%  

Financials

 LUPIN LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
DISHMAN PHARMA
Mar-16
LUPIN LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,127374 568.1%   
Low Rs1,294129 1,004.0%   
Sales per share (Unadj.) Rs304.1197.8 153.7%  
Earnings per share (Unadj.) Rs50.421.2 237.6%  
Cash flow per share (Unadj.) Rs60.734.7 174.8%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.40.8 55.2%  
Book value per share (Unadj.) Rs243.8179.9 135.5%  
Shares outstanding (eoy) m450.5880.69 558.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.61.3 442.1%   
Avg P/E ratio x33.911.9 286.0%  
P/CF ratio (eoy) x28.27.2 388.9%  
Price / Book Value ratio x7.01.4 501.6%  
Dividend payout %14.99.4 157.8%   
Avg Mkt Cap Rs m770,74020,306 3,795.7%   
No. of employees `00016.40.8 1,972.4%   
Total wages/salary Rs m21,0775,355 393.6%   
Avg. sales/employee Rs Th8,379.619,252.7 43.5%   
Avg. wages/employee Rs Th1,289.06,459.5 20.0%   
Avg. net profit/employee Rs Th1,388.72,064.1 67.3%   
INCOME DATA
Net Sales Rs m137,01615,961 858.5%  
Other income Rs m1,877265 707.2%   
Total revenues Rs m138,89316,226 856.0%   
Gross profit Rs m37,5354,103 914.8%  
Depreciation Rs m4,6351,091 425.0%   
Interest Rs m446944 47.2%   
Profit before tax Rs m34,3302,334 1,471.1%   
Minority Interest Rs m-880-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,536624 1,849.9%   
Profit after tax Rs m22,7071,711 1,327.0%  
Gross profit margin %27.425.7 106.6%  
Effective tax rate %33.626.7 125.7%   
Net profit margin %16.610.7 154.6%  
BALANCE SHEET DATA
Current assets Rs m97,79011,018 887.6%   
Current liabilities Rs m53,8729,517 566.1%   
Net working cap to sales %32.19.4 340.9%  
Current ratio x1.81.2 156.8%  
Inventory Days Days85110 76.6%  
Debtors Days Days12135 347.9%  
Net fixed assets Rs m86,37916,304 529.8%   
Share capital Rs m901161 558.4%   
"Free" reserves Rs m105,73512,907 819.2%   
Net worth Rs m109,84414,516 756.7%   
Long term debt Rs m53,7394,189 1,282.7%   
Total assets Rs m224,37829,805 752.8%  
Interest coverage x77.93.5 2,245.4%   
Debt to equity ratio x0.50.3 169.5%  
Sales to assets ratio x0.60.5 114.0%   
Return on assets %10.38.9 115.8%  
Return on equity %20.711.8 175.4%  
Return on capital %21.217.5 121.0%  
Exports to sales %49.124.8 198.0%   
Imports to sales %7.43.7 199.2%   
Exports (fob) Rs m67,2443,956 1,699.7%   
Imports (cif) Rs m10,199596 1,710.4%   
Fx inflow Rs m71,4054,952 1,442.1%   
Fx outflow Rs m17,807697 2,555.6%   
Net fx Rs m53,5984,255 1,259.7%   
CASH FLOW
From Operations Rs m-3,6902,786 -132.4%  
From Investments Rs m-69,434-1,529 4,541.5%  
From Financial Activity Rs m58,126-941 -6,176.4%  
Net Cashflow Rs m-14,998316 -4,740.2%  

Share Holding

Indian Promoters % 46.6 61.4 75.9%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 3.7 305.4%  
FIIs % 31.9 12.7 251.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 22.1 45.7%  
Shareholders   98,259 46,261 212.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare LUPIN LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 24, 2017 10:34 AM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - ORCHID PHARMA LTD COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS